Innate Pharma S.A. ADS Company Profile
NASDAQ: IPHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Innate Pharma S.A. at a glance
Innate Pharma S.A. ADS (NASDAQ: IPHA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Marseille, France. Innate Pharma S.A. is led by Mr. Jonathan E. Dickinson B.Sc., M.B.A. and employs about 120 people. The company's shares have traded publicly since 2019.
At a market capitalization of $96.4 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001598599, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Innate Pharma S.A. do?
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Business description based on the company's public filings.
Company information
- Legal name
- Innate Pharma S.A. ADS
- Ticker
- NASDAQ: IPHA
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Jonathan E. Dickinson B.Sc., M.B.A.
- Employees
- 120
- Headquarters
- 117, Avenue de Luminy, Marseille, France
- Phone
- 33 4 30 30 30 30
- Website
- innate-pharma.com
- IPO year
- 2019
- Market cap
- $96.44M
- SEC CIK
- 0001598599
Companies similar to Innate Pharma S.A.
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MOLNMolecular Partners AG ADR | 2.53 | -5.25% | $96.80M | vs IPHA |
| VYGRVoyager Therapeutics Inc. | 1.53 | -4.97% | $95.21M | vs IPHA |
| OTLKOutlook Therapeutics Inc. | 0.39 | -2.74% | $94.94M | vs IPHA |
| LENZLENZ Therapeutics Inc. | 2.97 | -11.23% | $93.16M | vs IPHA |
| ZURAZura Bio Limited Class A | 0.9305 | -2.30% | $89.63M | vs IPHA |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs IPHA |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs IPHA |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs IPHA |